April 16, 2025 10:38 AM EDT
News Briefing

No­var­tis ter­mi­nates knee pain study; Telix re­ports brain tu­mor da­ta

ENDPOINTS

Plus, news about Tiger Gene and Ther­at­e­ch­nolo­gies:

No­var­tis scraps knee pain drug: The Swiss drug­mak­er dis­con­tin­ued a

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times